Our results show that EGFR inhibition via reducing STAT3 phosphorylation sensitizes some GBM cells to treatment with TMZ or DOX, providing a new modality for those chemotherapeutic-resistant cells. The gene discussed is STAT3; the disease is glioblastoma.